What the ACR and SBI Say About the New USPSTF Breast Cancer Screening Guidelines

jay i
Jun 18
4 min read

Updated coverage of the ACR and SBI's response to USPSTF’s 2024 final recommendations on breast cancer screening.

1. Introduction

The United States Preventive Services Task Force (USPSTF) amended its recommendations on April 30, 2024, to recommend biannual (every two years) mammograms for average-risk women between the ages of 40 and 74. From their 2016 stance, which placed a strong focus on personal choices in their forties, this was a dramatic change.

The Society of Breast Imaging (SBI) and the American College of Radiology (ACR) issued a joint statement in response, encouraging the Task Force to endorse yearly screening starting at age 40 in order to maximize life-saving benefits while also applauding other aspects of the update.

2. Summary of USPSTF’s Updated Recommendations (April 30, 2024)

According to USPSTF’s final statement:

Average-risk women aged 40–74 should receive mammograms every two years (Grade B)
For women aged 75 and older, evidence was deemed insufficient to make a recommendation (Grade I)
Similarly, there was no clear recommendation on supplemental screening (e.g., MRI or ultrasound) for women with dense breasts

Based on modeling of mortality, false positives, and overdiagnosis, the panel came to the conclusion that biannual screening provides a favorable balance of benefits and hazards throughout this age range.

3. The ACR/SBI Stance: Annual Screening from Age 40

The ACR/SBI cautioned that biannual intervals are insufficient, but commended the update for starting screening at age 40. They insist that yearly mammograms save the greatest number of lives and call on the USPSTF to fully recommend yearly screening with a B-grade rating.

Additionally, they recommend:

Continued screening beyond age 74, unless severe comorbidities are present
Risk assessment by age 25, especially for populations at higher risk (e.g., Black or Ashkenazi Jewish women)
Tailored screening and MRI for dense breasts and high-risk groups
Inclusive guidance for transgender individuals based on their biological and hormonal profiles

4. Key Issues Highlighted by ACR/SBI

A. Annual vs. Biennial Screening

With an emphasis on modeling and clinical data showing that yearly intervals result in more life-years saved than biannual methods, ACR/SBI advocate annual screening starting at age 40.

B. Screening After Age 74

ACR/SBI emphasize that healthy women over 74 should continue screening until significant comorbidities lower life expectancy, even though the USPSTF stopped at age 74.

C. Supplemental Screening for Dense Breasts

For additional screening, USPSTF gave it a grade of "I" (insufficient evidence). However, ACR/SBI promote risk-stratified techniques and draw attention to the recognized danger and masking impact of thick breast tissue.D. Early Risk Assessment

ACR/SBI recommend that all women undergo risk assessment by age 25, with earlier surveillance as needed, especially for high-risk groups

E. Transgender and Hormonal Considerations

According to both organizations, transgender people should be tested for biological risk and hormone usage; for instance, hormone therapy may cause risk factors to emerge in transgender women.

5. Comparative Analysis: USPSTF vs. ACR/SBI vs. Other Organisations

Organization	Start Age	Screening Interval	Stop Age	Supplemental Screening	Risk Assessment
USPSTF	40	Every 2 years	74	Insufficient evidence (I)	—
ACR/SBI	40	Every year	No limit	Tailored MRI/ultrasound	By age 25
ACS	45 (optional 40)	Annually (45–54), biennial thereafter	Life expectancy >10 years	Depending on risk	Not specified
ACOG	40	1–2 years	75+ based on health	Recommend supplemental in high risk	—

6. Evidence Behind the Recommendations

The little incremental benefit of yearly screening may be exceeded by false positives and overdiagnosis, according to USPSTF-based biannual recommendations based on modeling and screening studies.

ACR/SBI refute, pointing to RCTs, observational research, and decision models that show annual screening reduces mortality and increases life-year gains.

7. Why Disparities Matter: The Case for Earlier and More Frequent Screening

Black, Ashkenazi Jewish, and other minority women have higher death rates and are disproportionately diagnosed with severe breast cancers at younger ages. Delaying to biannual intervals, according to ACR/SBI, might make these gaps wider.

8. Potential Harms: Overdiagnosis & False Positives

The USPSTF highlights the risks associated with overdiagnosis, false positives, and needless operations, especially for younger women.

Although ACR/SBI is aware of these concerns, they believe that the advantages of yearly screening still exceed them, particularly in cases where early identification saves lives.

9. Patient Perspective & Shared Decision-Making

Experts in medicine stress the value of collaborative decision-making, in which patients balance the advantages of early identification against the concerns and actions brought on by false positives.

10. Clinical Implications & Provider Advice

Providers should discuss screening options based on age, personal and family history, breast density, and comorbidities.
High-risk patients may benefit from MRI and earlier scans; guidelines emphasise individualised care.
Transgender patients must be assessed for risk in consultation with their current physiology and hormone status .

11. What Patients Should Do Next

Women 40–74 should seek mammograms at least biennially, and annually if advised.
Discuss personal risk factors with your provider, especially if you have dense breasts or family history.
Stay informed: ensure you receive the latest guidance and understand insurance coverage.
Monitor breast density, especially as changes may necessitate supplemental screening.
Continue screening past 74 if your health allows.

12. Future Research and Monitoring

Both USPSTF and ACR/SBI call for more evidence on:

Screening intervals for women over 74
Supplemental modalities in dense-breasted populations
Tailored screening to address racial and demographic disparities
Impact of AI-enhanced imaging tools

13. Conclusion

In comparison to previous age-delayed regimens, the USPSTF's new biannual screening guidelines for women aged 40–74 indicate progress. Nonetheless, early risk assessments, ongoing surveillance after age 74, and yearly screening starting at age 40 have a better potential to save lives, according to the ACR/SBI. Their forceful reaction emphasizes how crucial proactive, tailored decision-making is to lowering the death rate from breast cancer, particularly in underserved and high-risk communities.

Rinebraska is dedicated to delivering cutting-edge solutions tailored to meet the dynamic needs of healthcare providers and their patients. Get in touch with us for expert Diagnostic and Interventional Radiology services.